Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV
Darunavir exposures achieved in our trial are within safe range. Darunavir/ritonavir can safely be co-administered with TAF/FTC. Both WHO-recommended 600/100 mg and CHAPAS-4 800/100 mg darunavir/ritonavir doses for the 25-34.9 kg weight band offer favourable exposures. The choice between them can depend on tablet availability.
Authors
- Veronica Mulenga (ORCID: https://orcid.org/0000-0003-1843-8169)
- Alexander J. Szubert (ORCID: https://orcid.org/0000-0002-2082-0861)
- Chishala Chabala (ORCID: https://orcid.org/0000-0002-5551-5752)
- Hylke Waalewijn (ORCID: https://orcid.org/0000-0002-5135-8729)
- Helen McIlleron (ORCID: https://orcid.org/0000-0002-0982-6226)
- Victor Musiime (ORCID: https://orcid.org/0000-0001-7472-9054)
- Diana M. Gibb (ORCID: https://orcid.org/0000-0002-9738-5490)
- Angela Colbers (ORCID: https://orcid.org/0000-0002-0389-9934)
- Shaghayegh Mohsenian Naghani (ORCID: https://orcid.org/0000-0002-0051-2634)
- Paolo Denti (ORCID: https://orcid.org/0000-0001-7494-079X)
- Mariam Kasozi
- Mutsa Bwakura‐Dangarembizi (ORCID: https://orcid.org/0000-0001-7751-6177)
- Roeland E. Wasmann (ORCID: https://orcid.org/0000-0002-5769-8150)
- Lara Monkiewicz
- Diana Antonia Rutebarika
- Moses Chitsamatanga
- Abbas Lugemwa
- David M Burger
- Lufina Tsirizani
Institutions
- Radboud University Nijmegen (NL)
- University of Zimbabwe (ZW)
- University of Cape Town (ZA)
- University of Health Science (KH)
- University of Lusaka (ZM)
- Kamuzu Central Hospital (MW)
- University Teaching Hospital (ZM)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- Wellcome Centre for Infectious Diseases Research in Africa (ZA)
- Joint Clinical Research Centre (UG)
- Kamuzu University of Health Sciences (MW)
- University College London (GB)
- Makerere University (UG)
- Medical Research Council (GB)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1093/jac/dkae319
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- European Commission
- Universiteit Leiden
- Leids Universitair Medisch Centrum
- Norges Forskningsråd
- University of Cape Town
- National Institutes of Health
- Medical Research Council
- National Institute of Allergy and Infectious Diseases
- European and Developing Countries Clinical Trials Partnership